Trial
NCT03286114
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Michigan Rogel Cancer Center
Collaborators
Merck Sharp & Dohme LLC
Condition
Myelodysplastic Syndromes
Intervention
Pembrolizumab
Why stopped
Lack of patient population
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-11